Markets

Replimune to Resubmit Twice-Rejected Drug for FDA Approval After Agency Shakeup

Biotech company plans new application following FDA leadership changes, after previously criticizing agency for inconsistent guidance around trials.

Replimune to Resubmit Twice-Rejected Drug for FDA Approval After Agency Shakeup
Read the full reporting at CNBC Markets.

Originally reported by CNBC Markets.

Replimune FDA drug approval melanoma biotech pharmaceutical